Ovarian type epithelial tumor of the tunica vaginalis with abdominal metastasis

The incidence of skin cancer is a steady increasing around the world. Tumors of epithelial origin occupy the first place in the structure of all skin malignancy. Epidermoid carcinoma is the most malignant epithelial tumor of the skin and mucous membranes with squamous differentiation. Generally, squamous cell carcinoma is successfully treated by surgical and radiological methods. Often a different kind of plastic defect reconstructions are required after surgical removal. The incidence of epidermoid carcinoma increases with age (average age of patients falls on 65 years) therefore variants of treatment options is limited by comorbidities. However, surgical oncologist do not have enough date and randomized controlled studies on this theme. Minimally invasive methods, especially cryothechnology are increasingly used, but unfortunately their advantage requires additional evidence. We suppose Inclusion in the conventional treatment of new technologies may possibly improve the results of treatment. We reviewed the literature, summarizing data on various methods of treating squamous cell skin cancer. Comprehensive and systematic search was based on MedLine, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Scopus and PubMed among original articles for the period from January 1974 to October 2018.

Download Full-text

Calcifying nested stromal–epithelial tumor: a clinicopathologic and molecular genetic study of eight cases highlighting metastatic potential and recurrent CTNNB1 and TERT promoter alterations

Modern Pathology ◽

10.1038/s41379-021-00822-w ◽

2021 ◽

Author(s):

David J. Papke ◽

Fei Dong ◽

Xuchen Zhang ◽

Rafal Kozielski ◽

Olca Basturk ◽

...

Keyword(s):

Genetic Study ◽

Molecular Genetic ◽

Metastatic Potential ◽

Molecular Genetic Study ◽

Epithelial Tumor ◽

Tert Promoter

Download Full-text

BMI-1 Expression Heterogeneity in Endometriosis-Related and Non-Endometriotic Ovarian Carcinoma

International Journal of Molecular Sciences ◽

10.3390/ijms22116082 ◽

2021 ◽

Vol 22 (11) ◽

pp. 6082

Author(s):

Ludmila Lozneanu ◽

Raluca Anca Balan ◽

Ioana Păvăleanu ◽

Simona Eliza Giuşcă ◽

Irina-Draga Căruntu ◽

...

Keyword(s):

Stem Cells ◽

Statistical Analysis ◽

Ovarian Carcinoma ◽

Clinicopathological Characteristics ◽

Cell Phenotype ◽

Epithelial Tumor ◽

Normal Organ ◽

Ovarian Carcinogenesis ◽

Cellular Signaling Pathway ◽

The Relationship

BMI-1 is a key component of stem cells, which are essential for normal organ development and cell phenotype maintenance. BMI-1 expression is deregulated in cancer, resulting in the alteration of chromatin and gene transcription repression. The cellular signaling pathway that governs BMI-1 action in the ovarian carcinogenesis sequences is incompletely deciphered. In this study, we set out to analyze the immunohistochemical (IHC) BMI-1 expression in two different groups: endometriosis-related ovarian carcinoma (EOC) and non-endometriotic ovarian carcinoma (NEOC), aiming to identify the differences in its tissue profile. Methods: BMI-1 IHC expression has been individually quantified in epithelial and in stromal components by using adapted scores systems. Statistical analysis was performed to analyze the relationship between BMI-1 epithelial and stromal profile in each group and between groups and its correlation with classical clinicopathological characteristics. Results: BMI-1 expression in epithelial tumor cells was mostly low or negative in the EOC group, and predominantly positive in the NEOC group. Moreover, the stromal BMI-1 expression was variable in the EOC group, whereas in the NEOC group, stromal BMI-1 expression was mainly strong. We noted statistically significant differences between the epithelial and stromal BMI-1 profiles in each group and between the two ovarian carcinoma (OC) groups. Conclusions: Our study provides solid evidence for a different BMI-1 expression in EOC and NEOC, corresponding to the differences in their etiopathogeny. The reported differences in the BMI-1 expression of EOC and NEOC need to be further validated in a larger and homogenous cohort of study.

Download Full-text

Advanced Colon Cancer after Curative Resection of Intramucosal Adenocarcinoma with Endoscopic Submucosal Dissection

Case Reports in Gastroenterology ◽

10.1159/000516314 ◽

2021 ◽

pp. 603-609

Author(s):

Akiko Sasaki ◽

Chikamasa Ichita ◽

Chihiro Sumida ◽

Karen Kimura ◽

Takashi Nishino ◽

...

Keyword(s):

Elderly Patients ◽

Endoscopic Submucosal Dissection ◽

Advanced Cancer ◽

Curative Resection ◽

Submucosal Tumor ◽

R0 Resection ◽

Surveillance Colonoscopy ◽

Epithelial Tumor ◽

Submucosal Dissection ◽

Intramucosal Adenocarcinoma

Endoscopic resection, particularly endoscopic submucosal dissection (ESD), for colorectal cancers enables a precise pathological diagnosis and safe R0 resection. The recurrence rate after ESD is generally extremely low, with annual surveillance colonoscopy recommended. However, surveillance may not be considered for super-elderly patients owing to their condition. This is a case report of an 85-year-old man in whom curative resection was achieved for an intramucosal adenocarcinoma with ESD. The patient presented with a hypoechoic mass located in his lower right abdomen, diagnosed via surveillance abdominal ultrasound. He had undergone curative ESD for intramucosal cecal cancer 2 years prior. Colonoscopy revealed a type 2 epithelial tumor at the proximal aspect of the ESD scar. Ileocolic resection with lymph node dissection was performed. An epithelial tumor and well-differentiated adenocarcinoma but not a submucosal tumor was detected in the mucosal layer. The lesion was diagnosed not as a local recurrence after ESD but as a newly emerged original advanced cancer. After ESD for colorectal cancer, a newly developed advanced cancer may occur at the site of the ESD scar in a shorter term than usual. Surveillance colonoscopy after ESD is necessary even for super-elderly patients.

Download Full-text

Clear cell adenocarcinoma of the tunica vaginalis of the testis with an adjacent uterus-like tissue*

Pathology International ◽

10.1111/j.1440-1827.2004.01675.x ◽

2004 ◽

Vol 54 (8) ◽

pp. 641-647 ◽

Cited By ~ 11

Author(s):

Ozden Tulunay ◽

Cagatay Gogus ◽

Sumer Baltaci ◽

Safak Bulut

Keyword(s):

Clear Cell ◽

Clear Cell Adenocarcinoma ◽

Tunica Vaginalis

Download Full-text

Case report: potential treatment of metastatic amphicrine carcinoma of the rectum with FOLFOXIRI chemotherapy

Oxford Medical Case Reports ◽

10.1093/omcr/omaa097 ◽

2020 ◽

Vol 2020 (11) ◽

Author(s):

Nobumasa Tamura ◽

Yoshitaka Honma ◽

Shigeki Sekine ◽

Shunsuke Tsukamoto ◽

Hidekazu Hirano ◽

...

Keyword(s):

Progression Free Survival ◽

First Line ◽

Epithelial Tumor ◽

Carcinoma Of The Rectum ◽

Free Survival ◽

Lymph Nodes Dissection ◽

Multiple Liver Metastases ◽

Submucosal Lesion ◽

Line Chemotherapy ◽

Endocrine Features

ABSTRACT Amphicrine carcinoma (AmC) is a unique epithelial tumor displaying exocrine and endocrine features in the same cell. It shows an adenocarcinoma-like cellular form and has endocrine granules. There are few reports describing chemotherapy for AmC. Here, we describe a case with metastatic AmC from the rectum that was treated with FOLFOXIRI chemotherapy. A 64-year-old man was diagnosed with a submucosal lesion on the scar produced after an endoscopic mucosal resection, which had been performed for adenocarcinoma of the rectum 2 years before. The endoscopic submucosal dissection revealed AmC. The abdominoperineal resection including lymph nodes dissection was performed. Thereafter, computed tomography showed multiple liver metastases, and FOLFOXIRI was administered. The best overall response was partial response, and progression-free survival was 8.7 months. After 16.0 months since first-line chemotherapy the patient died. We can therefore conclude that FOLFOXIRI may be effective for AmC of the rectum.

Download Full-text